Cucurbitacin B (Triterpenoid)

Cucurbitacin B is a tetracyclic triterpenoid compound found in plants of the Cucurbitaceae family that demonstrates potent anti-cancer properties in laboratory studies. This bioactive compound works primarily by suppressing NF-κB signaling pathways and modulating MAPK/ERK cascades to inhibit tumor cell proliferation and metastasis.

Origin & History

Cucurbitacin B is a highly oxidized tetracyclic triterpenoid with molecular formula C32H46O8, naturally occurring in plants of the Cucurbitaceae family, including traditional Chinese medicinal herbs. It features a lanostane skeleton multi-substituted with hydroxy, methyl, and oxo groups, with unsaturation at positions 5 and 23, and an acetylated hydroxy at C-25.

Historical & Cultural Context

Cucurbitacin B is produced by plants in the Cucurbitaceae family, which comprise numerous traditional medicinal Chinese herbs. However, specific historical uses, durations, or traditional indications for isolated Cucurbitacin B are not documented in the available sources.

Health Benefits

• May inhibit tumor cell growth and metastasis through multiple cellular pathways (preliminary evidence from in vitro studies)
• Potential to suppress NF-κB activation and inflammatory responses (based on preclinical research only)
• Could reduce cellular proliferation via MAPK/ERK pathway modulation (animal and cell culture studies)
• May inhibit PI3K/Akt/mTOR signaling in cancer cells (laboratory evidence only)
• Possible reduction in DNA, RNA, and protein synthesis in tumor cells (in vitro data)

How It Works

Cucurbitacin B exerts its biological effects by suppressing nuclear factor-κB (NF-κB) activation, which reduces inflammatory cytokine production and tumor cell survival signals. The compound also modulates the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathway, leading to decreased cellular proliferation and increased apoptosis in cancer cells. Additionally, cucurbitacin B interferes with STAT3 signaling and disrupts actin filament organization, contributing to its anti-metastatic properties.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses for Cucurbitacin B were identified in the available research. All evidence comes from preclinical studies including in vitro and animal models demonstrating anti-proliferative effects through mechanisms like NF-κB inhibition.

Clinical Summary

Research on cucurbitacin B is primarily limited to in vitro cell culture studies and animal models, with no completed human clinical trials available. Laboratory studies have demonstrated IC50 values ranging from 0.1-10 μM against various cancer cell lines, including breast, lung, and colon cancer cells. Animal studies using doses of 1-5 mg/kg have shown tumor growth inhibition rates of 40-70% in xenograft models. However, the compound's high toxicity and lack of human safety data significantly limit its therapeutic potential and clinical translation.

Nutritional Profile

Cucurbitacin B is a highly oxygenated tetracyclic triterpenoid (molecular formula C32H48O8, MW ~560.7 g/mol) found in cucurbit plants (cucumber, bitter melon, squash). It is not a conventional nutrient and provides no meaningful macronutrient or micronutrient value. As a bioactive secondary metabolite, it occurs in plant tissues at trace concentrations typically ranging from 0.001–0.1% dry weight depending on plant species and tissue type. Concentrations in cucumber fruit are extremely low (<1 mg/kg fresh weight), while roots and leaves may contain higher amounts. Bioavailability is poorly characterized in humans; limited oral bioavailability is suspected due to poor aqueous solubility (log P ~3.5, indicating moderate lipophilicity), potential first-pass metabolism, and rapid plasma clearance observed in rodent pharmacokinetic studies. It is not a source of calories, protein, carbohydrates, fats, vitamins, or minerals in any nutritionally relevant quantity. Its relevance is entirely as a bioactive phytochemical with pharmacological properties. Typical experimental in vitro and in vivo doses range from nanomolar (nM) to low micromolar (µM) concentrations. Toxicity at higher doses is a significant concern, as cucurbitacins are responsible for the bitter taste and toxic properties of certain cucurbit plants. No established Dietary Reference Intake (DRI) or safe upper intake level exists for this compound.

Preparation & Dosage

No clinically studied dosage ranges, forms, or standardization details are available as human trials have not been conducted. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Other cucurbitacins, green tea polyphenols, curcumin, resveratrol, quercetin

Safety & Interactions

Cucurbitacin B exhibits significant cytotoxicity with narrow therapeutic windows in animal studies, causing gastrointestinal distress, hepatotoxicity, and potential bone marrow suppression at effective doses. The compound may interact with medications metabolized by cytochrome P450 enzymes, though specific drug interactions have not been well characterized. Pregnant and breastfeeding women should avoid exposure to cucurbitacin B due to its potent biological activity and lack of safety data. Currently, no standardized dosing guidelines exist for human use, and the compound is not approved for therapeutic applications.